pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
SHP611
Phase 2 · small molecule · Metachromatic Leukodystrophy (MLD)
SHP611 for Metachromatic Leukodystrophy (MLD) is a Phase 2 program (small_molecule) at Shire with 1 ClinicalTrials.gov record(s).
Internal code SHP611-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Metachromatic Leukodystrophy (MLD)
- Status
- active
- Trials
- 1